BETA
Your AI-Trained Oncology Knowledge Connection!
This slide show features various images of papillary, clear cell, chromophobe, and tubulocystic renal cell carcinoma.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
First-Line Radiotherapy Combo May Show Benefit in Oligoprogressive HCC
First-line systemic therapy plus radiation therapy improved PFS vs second-line systemic therapy with or without radiation in hepatocellular carcinoma.
A Sneak Peek at 2025 ASCO From the GU Perspective
Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.
Tivozanib Shows Efficacy in Pretreated Metastatic RCC
There appeared to be no extra benefit with the addition of nivolumab to tivozanib among patients included in the phase 3 TiNivo-2 trial.
Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer
Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.
CAN-2409/EBRT Improves Disease-Free Survival in Localized Prostate Cancer
The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.
Second-Line Cabozantinib Regimens Exhibit Efficacy in Advanced RCC
Efficacy and safety outcomes in the phase 3 CONTACT-03 study were consistent regardless of patients' prior immunotherapy or tyrosine kinase inhibitor use.